Aurinia Pharmaceuticals Inc
AUPH7.305USD
-0.175-2.34%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.01BMarktkapitalisierung
25.25KGV TTM
mehr Informationen über Aurinia Pharmaceuticals Inc Unternehmen
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Unternehmensinformationen
BörsenkürzelAUPH
Name des UnternehmensAurinia Pharmaceuticals Inc
IPO-datumJul 16, 2001
Gegründet am2009
CEOMr. Peter S. Greenleaf
Anzahl der mitarbeiter130
WertpapierartOrdinary Share
GeschäftsjahresendeJul 16
Addresse#140, 14315 - 118 Avenue
StadtEDMONTON
BörseNASDAQ Global Market Consolidated
LandCanada
PostleitzahlT5L 4S6
Telefon12507442487
Websitehttps://www.auriniapharma.com
BörsenkürzelAUPH
IPO-datumJul 16, 2001
Gegründet am2009
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Jun 30
Währung: USDAktualisiert: Mon, Jun 30
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: 16 hours ago
Aktualisiert: 16 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Aktionäre
Aktionäre
Anteil
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
14.35%
Investment Advisor
12.78%
Investment Advisor/Hedge Fund
12.71%
Corporation
6.57%
Venture Capital
3.02%
Research Firm
2.96%
Individual Investor
2.80%
Pension Fund
0.52%
Bank and Trust
0.35%
Other
43.95%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
436
77.25M
57.17%
-345.00
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
2023Q1
499
65.33M
45.73%
-27.23M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Tang Capital Management, LLC
10.03M
7.42%
+1.60M
+18.98%
Mar 31, 2025
ILJIN SNT Co., Ltd.
8.88M
6.57%
+2.48M
+38.78%
Apr 12, 2025
BlackRock Institutional Trust Company, N.A.
7.47M
5.53%
-150.03K
-1.97%
Mar 31, 2025
Armistice Capital LLC
5.00M
3.7%
-1.40M
-21.88%
Mar 31, 2025
New Enterprise Associates (NEA)
3.97M
2.94%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.85M
2.11%
-66.87K
-2.29%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.44%
+241.86K
+14.20%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
1.29%
+754.77K
+76.56%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.73M
1.28%
-30.09K
-1.71%
Mar 31, 2025
Arrowstreet Capital, Limited Partnership
1.64M
1.21%
+564.52K
+52.47%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 8 hours ago
Aktualisiert: 8 hours ago
Name
Anteil
Virtus LifeSci Biotech Products ETF
1.48%
ALPS Medical Breakthroughs ETF
0.93%
Janus Henderson Small Cap Growth Alpha ETF
0.7%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Vanguard US Momentum Factor ETF
0.1%
iShares Biotechnology ETF
0.1%
Vanguard US Multifactor ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
Mehr Anzeigen
Virtus LifeSci Biotech Products ETF
Anteil1.48%
ALPS Medical Breakthroughs ETF
Anteil0.93%
Janus Henderson Small Cap Growth Alpha ETF
Anteil0.7%
SPDR S&P International Small Cap ETF
Anteil0.14%
Invesco Nasdaq Biotechnology ETF
Anteil0.12%
ProShares Ultra Nasdaq Biotechnology
Anteil0.12%
Vanguard US Momentum Factor ETF
Anteil0.1%
iShares Biotechnology ETF
Anteil0.1%
Vanguard US Multifactor ETF
Anteil0.1%
Avantis US Small Cap Equity ETF
Anteil0.09%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
